Precision Biosciences Inc. (DTIL) is a leading life sciences company that specializes in genome editing technology. Established in 2006 and based in Durham, North Carolina, the company utilizes a proprietary platform named the ARCUS® platform, designed for effective genomic modifications in a range of organisms and cell types.
The heart of the company lies in its commitment to developing life-altering therapies for patients with genetic disorders or cancers that could be significantly addressed by gene editing. By using the ARCUS® Genome Editing technique, Precision Biosciences aims to overcome challenges associated with traditional genome editing techniques.
The company has formed several partnerships with pharmaceutical companies and biomedical researchers to apply their technology in various therapeutic areas. Its genome editing technique has potential applications in diverse fields, including human therapy, agricultural biotechnology, and industrial biotechnology.
In the field of human therapy, Precision Biosciences' most advanced program is in the immune-oncology space with their proprietary allogeneic CAR T therapy, targeting various hematological malignancies and solid tumors. The unique aspect of their therapy is the "off-the-shelf" availability, unlike most available CAR T therapies which require individualized processing for each patient.
In the ag-bio section, Precision Biosciences' team has developed a new, high-quality form of healthy wheat by removing the gene responsible for a troublesome allergen, which benefits millions of people globally who are sensitive to it.
Similarly, in the spectrum of industrial bio, Precision Biosciences works to perfect the yeast strains that produce vinegar for both medicinal and industrial applications.
Furthermore, Precision's team of committed individuals has a unique blend of skillsets in molecular biology, chemistry, and engineering that fuel their innovations. The company has consistently shown the ability to deliver competitive solutions in the area of genomic correction and transformation.
Precisely focused on its mission to “transform life,” Precision Biosciences continues to make strides to bring about therapeutic advances that will enhance the lives of patients with genetic diseases and cancer. The team at Precision Biosciences believes in the immense potential of genome editing and is consciously working towards realizing significant advancements in the field. With strong leadership, an innovative spirit, and steadfast determination, Precision Biosciences is well poised to continue leading the frontiers of genomic medicine.